Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity

W. F. Cheng, C. N. Lee, Y. N. Su, C. Y. Chai, M. C. Chang, J. M. Polo, Chien-Fu Hung, Tzyy Choou Wu, C. Y. Hsieh, C. A. Chen

Research output: Contribution to journalArticle

Abstract

Alphavirus vectors have emerged as a promising strategy for the development of cancer vaccines and gene therapy applications. In this study, we used the replication-defective vaccine vector SIN replicon particles from a new packaging cell line (PCL) to develop SIN replicon particles encoding calreticulin (CRT) linked to a model tumor antigen, human papillomavirus type 16 (HPV16) E7 protein. The linkage of CRT to E7 in SIN replicon particles resulted in a significant increase in E7-specific CD8+ T-cell precursors and a strong antitumor effect against E7-expressing tumors in vaccinated mice. SINrep5-CRT/E7 replicon particles enhanced presentation of E7 through the major histocompatibility complex (MHC) class I pathway by infecting dendritic cells (DCs) directly and pulsing DCs with lysates of cells infected by SINrep5-CRT/E7 replicons. Vaccination of immunocompromised (BALB/c nu/nu) mice with SINrep5-CRT/E7 replicon particles also generated significant reduction of lung tumor nodules, suggesting that antiangiogenesis may contribute to the antitumor effect of SINrep5-CRT/E7 replicon particles. Furthermore, SINrep5-CRT/E7 replicon particles generated long-term in vivo tumor protection effects and antigen-specific memory immunities. We concluded that the CRT strategy used in the context of SIN replicon particles facilitated the generation of a highly effective vaccine for cancer prophylaxis and immunotherapy.

Original languageEnglish (US)
Pages (from-to)873-885
Number of pages13
JournalCancer Gene Therapy
Volume13
Issue number9
DOIs
StatePublished - Sep 27 2006

Fingerprint

Calreticulin
Sindbis Virus
Replicon
Neoplasm Antigens
Virion
Immunity
Neoplasms
Cancer Vaccines
Dendritic Cells
Papillomavirus E7 Proteins
T-Lymphoid Precursor Cells
Alphavirus
Active Immunotherapy
Human papillomavirus 16
Neoplasm Genes
Product Packaging
Major Histocompatibility Complex
Genetic Therapy
Immunotherapy
Vaccination

Keywords

  • Alphavirus replicon
  • Angiogenesis
  • Cancer vaccine
  • Human papillomavirus
  • Immunotherapy
  • T-cell immunity

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Cheng, W. F., Lee, C. N., Su, Y. N., Chai, C. Y., Chang, M. C., Polo, J. M., ... Chen, C. A. (2006). Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity. Cancer Gene Therapy, 13(9), 873-885. https://doi.org/10.1038/sj.cgt.7700956

Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity. / Cheng, W. F.; Lee, C. N.; Su, Y. N.; Chai, C. Y.; Chang, M. C.; Polo, J. M.; Hung, Chien-Fu; Wu, Tzyy Choou; Hsieh, C. Y.; Chen, C. A.

In: Cancer Gene Therapy, Vol. 13, No. 9, 27.09.2006, p. 873-885.

Research output: Contribution to journalArticle

Cheng, W. F. ; Lee, C. N. ; Su, Y. N. ; Chai, C. Y. ; Chang, M. C. ; Polo, J. M. ; Hung, Chien-Fu ; Wu, Tzyy Choou ; Hsieh, C. Y. ; Chen, C. A. / Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity. In: Cancer Gene Therapy. 2006 ; Vol. 13, No. 9. pp. 873-885.
@article{ae407f998748458dbfc0b56ad3b24eb2,
title = "Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity",
abstract = "Alphavirus vectors have emerged as a promising strategy for the development of cancer vaccines and gene therapy applications. In this study, we used the replication-defective vaccine vector SIN replicon particles from a new packaging cell line (PCL) to develop SIN replicon particles encoding calreticulin (CRT) linked to a model tumor antigen, human papillomavirus type 16 (HPV16) E7 protein. The linkage of CRT to E7 in SIN replicon particles resulted in a significant increase in E7-specific CD8+ T-cell precursors and a strong antitumor effect against E7-expressing tumors in vaccinated mice. SINrep5-CRT/E7 replicon particles enhanced presentation of E7 through the major histocompatibility complex (MHC) class I pathway by infecting dendritic cells (DCs) directly and pulsing DCs with lysates of cells infected by SINrep5-CRT/E7 replicons. Vaccination of immunocompromised (BALB/c nu/nu) mice with SINrep5-CRT/E7 replicon particles also generated significant reduction of lung tumor nodules, suggesting that antiangiogenesis may contribute to the antitumor effect of SINrep5-CRT/E7 replicon particles. Furthermore, SINrep5-CRT/E7 replicon particles generated long-term in vivo tumor protection effects and antigen-specific memory immunities. We concluded that the CRT strategy used in the context of SIN replicon particles facilitated the generation of a highly effective vaccine for cancer prophylaxis and immunotherapy.",
keywords = "Alphavirus replicon, Angiogenesis, Cancer vaccine, Human papillomavirus, Immunotherapy, T-cell immunity",
author = "Cheng, {W. F.} and Lee, {C. N.} and Su, {Y. N.} and Chai, {C. Y.} and Chang, {M. C.} and Polo, {J. M.} and Chien-Fu Hung and Wu, {Tzyy Choou} and Hsieh, {C. Y.} and Chen, {C. A.}",
year = "2006",
month = "9",
day = "27",
doi = "10.1038/sj.cgt.7700956",
language = "English (US)",
volume = "13",
pages = "873--885",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity

AU - Cheng, W. F.

AU - Lee, C. N.

AU - Su, Y. N.

AU - Chai, C. Y.

AU - Chang, M. C.

AU - Polo, J. M.

AU - Hung, Chien-Fu

AU - Wu, Tzyy Choou

AU - Hsieh, C. Y.

AU - Chen, C. A.

PY - 2006/9/27

Y1 - 2006/9/27

N2 - Alphavirus vectors have emerged as a promising strategy for the development of cancer vaccines and gene therapy applications. In this study, we used the replication-defective vaccine vector SIN replicon particles from a new packaging cell line (PCL) to develop SIN replicon particles encoding calreticulin (CRT) linked to a model tumor antigen, human papillomavirus type 16 (HPV16) E7 protein. The linkage of CRT to E7 in SIN replicon particles resulted in a significant increase in E7-specific CD8+ T-cell precursors and a strong antitumor effect against E7-expressing tumors in vaccinated mice. SINrep5-CRT/E7 replicon particles enhanced presentation of E7 through the major histocompatibility complex (MHC) class I pathway by infecting dendritic cells (DCs) directly and pulsing DCs with lysates of cells infected by SINrep5-CRT/E7 replicons. Vaccination of immunocompromised (BALB/c nu/nu) mice with SINrep5-CRT/E7 replicon particles also generated significant reduction of lung tumor nodules, suggesting that antiangiogenesis may contribute to the antitumor effect of SINrep5-CRT/E7 replicon particles. Furthermore, SINrep5-CRT/E7 replicon particles generated long-term in vivo tumor protection effects and antigen-specific memory immunities. We concluded that the CRT strategy used in the context of SIN replicon particles facilitated the generation of a highly effective vaccine for cancer prophylaxis and immunotherapy.

AB - Alphavirus vectors have emerged as a promising strategy for the development of cancer vaccines and gene therapy applications. In this study, we used the replication-defective vaccine vector SIN replicon particles from a new packaging cell line (PCL) to develop SIN replicon particles encoding calreticulin (CRT) linked to a model tumor antigen, human papillomavirus type 16 (HPV16) E7 protein. The linkage of CRT to E7 in SIN replicon particles resulted in a significant increase in E7-specific CD8+ T-cell precursors and a strong antitumor effect against E7-expressing tumors in vaccinated mice. SINrep5-CRT/E7 replicon particles enhanced presentation of E7 through the major histocompatibility complex (MHC) class I pathway by infecting dendritic cells (DCs) directly and pulsing DCs with lysates of cells infected by SINrep5-CRT/E7 replicons. Vaccination of immunocompromised (BALB/c nu/nu) mice with SINrep5-CRT/E7 replicon particles also generated significant reduction of lung tumor nodules, suggesting that antiangiogenesis may contribute to the antitumor effect of SINrep5-CRT/E7 replicon particles. Furthermore, SINrep5-CRT/E7 replicon particles generated long-term in vivo tumor protection effects and antigen-specific memory immunities. We concluded that the CRT strategy used in the context of SIN replicon particles facilitated the generation of a highly effective vaccine for cancer prophylaxis and immunotherapy.

KW - Alphavirus replicon

KW - Angiogenesis

KW - Cancer vaccine

KW - Human papillomavirus

KW - Immunotherapy

KW - T-cell immunity

UR - http://www.scopus.com/inward/record.url?scp=33747280364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747280364&partnerID=8YFLogxK

U2 - 10.1038/sj.cgt.7700956

DO - 10.1038/sj.cgt.7700956

M3 - Article

C2 - 16645621

AN - SCOPUS:33747280364

VL - 13

SP - 873

EP - 885

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 9

ER -